• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

按年龄划分的多发性硬化症患者疾病修饰治疗处方模式。

Disease-modifying therapy prescription patterns in people with multiple sclerosis by age.

作者信息

Zhang Yinan, Salter Amber, Jin Shan, Culpepper William J, Cutter Gary R, Wallin Mitchell, Stuve Olaf

机构信息

Department of Neurology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.

Division of Biostatistics, Washington University School of Medicine, St. Louis, MO, USA.

出版信息

Ther Adv Neurol Disord. 2021 Mar 31;14:17562864211006499. doi: 10.1177/17562864211006499. eCollection 2021.

DOI:10.1177/17562864211006499
PMID:33868459
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8020738/
Abstract

BACKGROUND

Disease-modifying therapies (DMTs) for multiple sclerosis (MS) are approved for their ability to reduce disease activity, namely clinical relapses and signal changes on magnetic resonance imaging (MRI). Disease activity appears age dependent. Thus, the greatest benefit would be expected in younger people with MS (PwMS) whereas benefits in the elderly are uncertain.

METHODS

Real-world data were obtained from PwMS from the North American Research Committee on Multiple Sclerosis (NARCOMS) registry and the US Department of Veterans Affairs Multiple Sclerosis Surveillance Registry (MSSR).

RESULTS

6948 PwMS were surveyed from NARCOMS, and the MSSR had 1719 participants. In younger adult PwMS 40-years old or less, 183 (61.4%) in NARCOMS and 179 (70.5%) in the MSSR were prescribed DMTs. Among PwMS over age 60, 1575 (40.1%) in NARCOMS and 239 (36.3%) in the MSSR were prescribed DMTs. More PwMS in the age group of 31-40 ( = 0.035) and 41-50 ( = 0.001) in the MSSR were using DMTs compared with PwMS of the same age groups in NARCOMS.

CONCLUSION

These findings suggest that DMTs are under-utilized in the younger population and continue to be commonly prescribed in the elderly. Broader access may explain the higher prescription rate of DMTs in US veterans.

摘要

背景

用于治疗多发性硬化症(MS)的疾病修正疗法(DMTs)因其降低疾病活动度的能力而被批准使用,疾病活动度具体表现为临床复发和磁共振成像(MRI)上的信号变化。疾病活动度似乎与年龄有关。因此,预计年轻的多发性硬化症患者(PwMS)能从中获得最大益处,而老年人的获益尚不确定。

方法

实际数据来自北美多发性硬化症研究委员会(NARCOMS)登记处的PwMS以及美国退伍军人事务部多发性硬化症监测登记处(MSSR)。

结果

对NARCOMS登记处的6948名PwMS进行了调查,MSSR有1719名参与者。在40岁及以下的年轻成年PwMS中,NARCOMS登记处有183名(61.4%)、MSSR有179名(70.5%)使用了DMTs。在60岁以上的PwMS中,NARCOMS登记处有1575名(40.1%)、MSSR有239名(36.3%)使用了DMTs。与NARCOMS登记处同年龄组的PwMS相比,MSSR中31 - 40岁(= 0.035)和41 - 50岁(= 0.001)年龄组使用DMTs的PwMS更多。

结论

这些发现表明,DMTs在年轻人群中未得到充分利用,而在老年人中仍被普遍使用。更广泛的获取途径可能解释了美国退伍军人中DMTs较高的处方率。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3bdb/8020738/b4939d6dc692/10.1177_17562864211006499-fig2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3bdb/8020738/24ce34eda23b/10.1177_17562864211006499-fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3bdb/8020738/b4939d6dc692/10.1177_17562864211006499-fig2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3bdb/8020738/24ce34eda23b/10.1177_17562864211006499-fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3bdb/8020738/b4939d6dc692/10.1177_17562864211006499-fig2.jpg

相似文献

1
Disease-modifying therapy prescription patterns in people with multiple sclerosis by age.按年龄划分的多发性硬化症患者疾病修饰治疗处方模式。
Ther Adv Neurol Disord. 2021 Mar 31;14:17562864211006499. doi: 10.1177/17562864211006499. eCollection 2021.
2
As time goes by: Treatment challenges in elderly people with multiple sclerosis.随着时间的推移:多发性硬化症老年患者的治疗挑战。
J Neuroimmunol. 2024 Jun 15;391:578368. doi: 10.1016/j.jneuroim.2024.578368. Epub 2024 May 14.
3
Indirect impact of the COVID-19 pandemic on the care and outcomes of people with MS: A combined survey and insurance claims study.2019冠状病毒病大流行对多发性硬化症患者护理及预后的间接影响:一项综合调查与保险理赔研究
Mult Scler Relat Disord. 2023 Dec;80:105085. doi: 10.1016/j.msard.2023.105085. Epub 2023 Oct 16.
4
Trajectories of disease-modifying therapies and associated sickness absence and disability pension among 1923 people with multiple sclerosis in Sweden.瑞典1923例多发性硬化症患者的疾病改善治疗轨迹及相关病假和残疾抚恤金情况
Mult Scler Relat Disord. 2023 Jan;69:104456. doi: 10.1016/j.msard.2022.104456. Epub 2022 Dec 9.
5
Disease-modifying therapy initiation patterns in multiple sclerosis in three large MS populations.三个大型多发性硬化症群体中疾病修饰疗法的起始模式
Ther Adv Neurol Disord. 2024 Mar 15;17:17562864241233044. doi: 10.1177/17562864241233044. eCollection 2024.
6
Use of the new oral disease-modifying therapies for multiple sclerosis in British Columbia, Canada: the first five-years.加拿大不列颠哥伦比亚省新的多发性硬化症口服疾病修正疗法的使用:头五年。
Mult Scler Relat Disord. 2018 Oct;25:57-60. doi: 10.1016/j.msard.2018.07.012. Epub 2018 Jul 9.
7
Selection of disease modifying therapies in multiple sclerosis based on patient's age and disease activity: Data from a nationwide registry.基于患者年龄和疾病活动度选择多发性硬化症的疾病修正疗法:来自全国登记处的数据。
J Neurol Sci. 2024 Jun 15;461:123052. doi: 10.1016/j.jns.2024.123052. Epub 2024 May 16.
8
A snapshot on patient-reported outcome measures of people with multiple sclerosis on first-line therapies in a real world setting.在真实世界环境中,一线治疗的多发性硬化症患者报告结局指标的快照。
Neurol Sci. 2020 Nov;41(11):3235-3241. doi: 10.1007/s10072-020-04367-9. Epub 2020 May 10.
9
Barriers to access and utilization of multiple sclerosis care services in a large cohort of Latin American patients.在一个大型拉丁美洲患者队列中,多发性硬化症护理服务获取和利用的障碍。
Mult Scler. 2021 Jan;27(1):117-129. doi: 10.1177/1352458519898590. Epub 2020 Jan 21.
10
Risk of Getting COVID-19 in People With Multiple Sclerosis: A Case-Control Study.多发性硬化症患者感染 COVID-19 的风险:一项病例对照研究。
Neurol Neuroimmunol Neuroinflamm. 2022 Jan 19;9(2). doi: 10.1212/NXI.0000000000001141. Print 2022 Mar.

引用本文的文献

1
Treatment Satisfaction with Teriflunomide in Patients with Multiple Sclerosis: A Systematic Review of Observational Studies.多发性硬化症患者对特立氟胺的治疗满意度:观察性研究的系统评价
Med J Islam Repub Iran. 2024 Dec 11;38:146. doi: 10.47176/mjiri.38.146. eCollection 2024.
2
Patient Experiences with the Impacts of Multiple Sclerosis & Disease-Modifying Therapies.多发性硬化症及疾病修正治疗影响的患者体验
Clinicoecon Outcomes Res. 2025 Mar 15;17:199-215. doi: 10.2147/CEOR.S489929. eCollection 2025.
3
Reasons for Hospital Admission in Individuals With Multiple Sclerosis.

本文引用的文献

1
Discontinuation of disease-modifying treatments for multiple sclerosis in patients aged over 50 with disease Inactivity.50岁以上病情无活动的多发性硬化症患者停用疾病修正治疗
J Neurol. 2020 Dec;267(12):3518-3527. doi: 10.1007/s00415-020-10029-9. Epub 2020 Jul 2.
2
Impact of Age on Multiple Sclerosis Disease Activity and Progression.年龄对多发性硬化症疾病活动和进展的影响。
Curr Neurol Neurosci Rep. 2020 May 26;20(7):24. doi: 10.1007/s11910-020-01046-2.
3
The Multiple Sclerosis Surveillance Registry: A Novel Interactive Database Within the Veterans Health Administration.
多发性硬化症患者的住院原因。
Int J MS Care. 2024 Oct 28;26(Q4):302-307. doi: 10.7224/1537-2073.2023-064. eCollection 2024 Oct.
4
De-escalation and Discontinuation of Disease-Modifying Therapies in Multiple Sclerosis.多发性硬化症中疾病修正疗法的降级和停药。
Curr Neurol Neurosci Rep. 2024 Sep;24(9):341-353. doi: 10.1007/s11910-024-01355-w. Epub 2024 Jul 12.
5
Adverse effects of immunotherapies for multiple sclerosis: a network meta-analysis.免疫疗法治疗多发性硬化症的不良反应:一项网络荟萃分析。
Cochrane Database Syst Rev. 2023 Nov 30;11(11):CD012186. doi: 10.1002/14651858.CD012186.pub2.
6
Treatment Patterns by Race and Ethnicity in Newly Diagnosed Persons with Multiple Sclerosis.新诊断多发性硬化症患者的种族和族裔治疗模式
Drugs Real World Outcomes. 2023 Dec;10(4):565-575. doi: 10.1007/s40801-023-00387-x. Epub 2023 Sep 21.
7
Humoral response to COVID-19 vaccination in MS patients on disease modifying therapy: Immune profiles and clinical outcomes.COVID-19 疫苗接种在接受疾病修正治疗的 MS 患者中的体液反应:免疫特征和临床结局。
Mult Scler Relat Disord. 2022 Nov;67:104079. doi: 10.1016/j.msard.2022.104079. Epub 2022 Jul 28.
8
Multiple Sclerosis: Systemic Challenges to Cost-Effective Care.多发性硬化症:经济有效护理面临的系统性挑战。
Am Health Drug Benefits. 2022 Mar;15(1):13-20.
9
Evolution of Disease Modifying Therapy Benefits and Risks: An Argument for De-escalation as a Treatment Paradigm for Patients With Multiple Sclerosis.疾病修饰疗法的益处与风险的演变:关于将逐步降级作为多发性硬化症患者治疗范例的观点
Front Neurol. 2022 Jan 25;12:799138. doi: 10.3389/fneur.2021.799138. eCollection 2021.
10
Disease-Modifying Drug Uptake and Health Service Use in the Ageing MS Population.老龄化 MS 人群中的疾病修正药物摄取和卫生服务利用。
Front Immunol. 2022 Jan 13;12:794075. doi: 10.3389/fimmu.2021.794075. eCollection 2021.
多发性硬化症监测登记处:退伍军人健康管理局内的一个新型交互式数据库。
Fed Pract. 2020 Apr;37(Suppl 1):S18-S23.
4
Patient-specific factors modulate leukocyte response in dimethyl fumarate treated MS patients.个体患者因素调节用二甲基富马酸治疗的多发性硬化症患者的白细胞反应。
PLoS One. 2020 Feb 11;15(2):e0228617. doi: 10.1371/journal.pone.0228617. eCollection 2020.
5
Informing Medication Discontinuation Decisions among Older Adults with Relapsing-Onset Multiple Sclerosis.告知复发缓解型多发性硬化症老年患者停药决策。
Drugs Aging. 2020 Mar;37(3):225-235. doi: 10.1007/s40266-019-00741-1.
6
Infection Risks Among Patients With Multiple Sclerosis Treated With Fingolimod, Natalizumab, Rituximab, and Injectable Therapies.多发性硬化症患者接受芬戈莫德、那他珠单抗、利妥昔单抗和注射治疗的感染风险。
JAMA Neurol. 2020 Feb 1;77(2):184-191. doi: 10.1001/jamaneurol.2019.3365.
7
Discontinuation of disease-modifying therapy for patients with relapsing-remitting multiple sclerosis: Effect on clinical and MRI outcomes.复发缓解型多发性硬化症患者停止疾病修正治疗:对临床和 MRI 结果的影响。
Mult Scler Relat Disord. 2019 Oct;35:119-127. doi: 10.1016/j.msard.2019.07.021. Epub 2019 Jul 25.
8
Comparative efficacy and acceptability of disease-modifying therapies in patients with relapsing-remitting multiple sclerosis: a systematic review and network meta-analysis.比较复发缓解型多发性硬化症患者的疾病修正治疗的疗效和可接受性:系统评价和网络荟萃分析。
J Neurol. 2020 Dec;267(12):3489-3498. doi: 10.1007/s00415-019-09395-w. Epub 2019 May 25.
9
Epidemiology and treatment of multiple sclerosis in elderly populations.老年人多发性硬化症的流行病学和治疗。
Nat Rev Neurol. 2019 Jun;15(6):329-342. doi: 10.1038/s41582-019-0183-3.
10
The prevalence of MS in the United States: A population-based estimate using health claims data.美国多发性硬化症的患病率:基于健康索赔数据的人群估计。
Neurology. 2019 Mar 5;92(10):e1029-e1040. doi: 10.1212/WNL.0000000000007035. Epub 2019 Feb 15.